Acute treatment of trigeminal neuralgia with onabotulinum toxin A

Clinical Neuropharmacology

Volumn 36, Issue 5, 2013, Pages 146-150

  Zúñiga, Carlos ^a   Piedimonte, Fabian ^b   Díaz, Sergio ^a   Micheli, Federico ^a  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

onabotulinum toxin A; pain; trigeminal neuralgia

Indexed keywords

AMITRIPTYLINE; BOTULINUM TOXIN A; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PLACEBO; SODIUM CHLORIDE;

ADULT; AGED; ALLODYNIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FACE ASYMMETRY; FACE PAIN; FEMALE; HEMATOMA; HUMAN; MALE; MASSETER MUSCLE; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TRIGEMINAL NERVE; TRIGEMINUS NEURALGIA; VISUAL ANALOG SCALE;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; TIME FACTORS; TRIGEMINAL NEURALGIA;

EID: 84885045036     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31829cb60e     Document Type: Article

References (25)

1. Merskey H, Bogduk N. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. Seattle, WA: IASP Press; 1994;59-71.
2. Katusic S, Williams DB, Beard CM, et al. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology 1991;10:276-281.
3. Bahgat D, Ray DK, Raslan AM, et al. Trigeminal neuralgia in young adults. J Neurosurg 2011;114:1306-1311.
4. van Kleef M, van Genderen WE, Narouze S, et al. 1. Trigeminal neuralgia. Pain Pract 2009;9:252-259.
5. Chakravarthi PS, Ghanta R, Kattimani V. Microvascular decompression treatment for trigeminal neuralgia. J Craniofac Surg 2011;22:894-898.
6. Park KJ, Kano H, Berkowitz O, et al. Computed tomography-guided ? knife stereotactic radiosurgery for trigeminal neuralgia. Acta Neurochir (Wien) 2011;153:1601-1609.
7. Koopman JS, de Vries LM, Dieleman JP, et al. A nationwide study of three invasive treatments for trigeminal neuralgia. Pain 2011;152: 507-513.
8. Pollock BE, Stein KJ. Surgical management of trigeminal neuralgia patients with recurrent or persistent pain despite three or more prior operations. World Neurosurg 2010;73:523-528.
9. Zúñiga C, Díaz P, Piedimonte F, et al. Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq Neuropsiquiatr 2008;66: 500-503.
10. Bergenheim AT, Asplund B, Linderoth P. Percutaneous retrogasserian balloon compression for trigeminal neuralgia: review of critical technical details and outcomes. World Neurosurg 2013;79:359-368.
11. Micheli F, Scorticati MC, Raina G. Beneficial effects of botulinum toxin type A for patients with painful tic convulsif. Clin Neuropharmacol 2002;25:260-262.
12. Ngeow WC, Nair R. Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109:e47-e50.
13. Nurmikko T, Cruccu G. Botulinum toxin for trigeminal neuralgia. Eur J Neurol 2009;16:104.
14. Boscá-Blasco ME, Burguera-Hernández JA, Roig-Morata S, et al. Painful tic convulsif and botulinum toxin. Rev Neurol 2006;42:729-732.
15. Volcy M, Tepper SJ, Rapoport AM, et al. Botulinum toxin A for the treatment of greater occipital neuralgia and trigeminal neuralgia: a case report with pathophysiological considerations. Cephalalgia 2006;26:336-340.
16. Allam N, Brasil-Neto JP, Brown G, et al. Injections of botulinum toxin type A produce pain alleviation in intractable trigeminal neuralgia. Clin J Pain 2005;21:182-184.
17. Bohluli B, Motamedi MH, Bagheri SC, et al. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;111:47-50.
18. Türk U, Ilhan S, Alp R, et al. Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol 2005;28:161-162.
19. Borodic GE, Acquadro MA. The use of botulinum toxin for the treatment of chronic facial pain. J Pain 2002;3:21-27.
20. Wang A, Jankovic J. Hemifacial spasm: clinical findings and treatment. Muscle Nerve 1998;21:1740-1747.
21. Wu CJ, Lian YJ, Zheng YK, et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia 2012;32:443-450.
22. Arezzo JC. Possible mechanisms for the effects of botulinum A toxin on pain. Clin J Pain 2002;18:S125-S132.
23. Gazerani P, Pedersen NS, Staahl C, et al. Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009;141:60-69.
24. Bigalke H, Heller I, Bizzini B, et al. Tetanus toxin and botulinum A toxin inhibit release and uptake of various transmitters, as studied with particulate preparations from rat brain and spinal cord. Naunyn Schmiedebergs Arch Pharmacol 1981;316:244-251.
25. McMahon HT, Foran P, Dolly JO, et al. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. J Biol Chem 1992;267:21338-21343.